Nuvalent, Inc. (NUVL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. James R. Porter Ph.D. | CEO, President & Director | 1.08M | 7.07M | 1976 |
| Prof. Matthew D. Shair Ph.D. | Founder, Head of Scientific Advisory Board & Director | 241.53k | -- | 1969 |
| Ms. Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer & Secretary | 681.8k | 4.32M | 1976 |
| Ms. Darlene Noci | Chief Development Officer | 670.1k | 3.08M | 1978 |
| Dr. Christopher D. Turner M.D. | Chief Medical Officer | 771.2k | -- | 1969 |
| Dr. Benjamin Lane Ph.D. | Senior Vice President of Technical Operations | -- | -- | -- |
| Dr. Henry Pelish Ph.D. | Chief Scientific Officer | -- | -- | 1973 |
| Mr. Matthew Metivier M.B.A. | Senior Vice President of Human Resources | -- | -- | -- |
| Mr. John Soglia Ph.D. | Senior Vice President of Translational Development | -- | -- | -- |
Nuvalent, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 142
Description
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available